Abstract
Studies on animal models have demonstrated that feeding a low-arginine diet inhibits triacylglycerol (TAG) secretion from the liver, resulting in marked fatty liver development in rats. Here, we first showed that culturing hepatocytes in the medium mimicking the serum amino acid profile of low-arginine diet-fed rats induced TAG accumulation in the cells, indicating that the specific amino acid profile caused TAG accumulation in hepatocytes. Dietary adenine supplementation completely recovered hepatic TAG secretion and abolished hepatic TAG accumulation in rats. A comprehensive non-linear analysis revealed that inhibition of hepatic TAG accumulation by dietary adenine supplementation could be predicted using only serum amino acid concentration data. Comparison of serum amino acid concentrations indicated that histidine, methionine, and branched-chain amino acid (BCAA) concentrations were altered by adenine supplementation. Furthermore, when the serum amino acid profiles of low-arginine diet-fed rats were altered by modifying methionine or BCAA concentrations in their diets, their hepatic TAG accumulation was abolished. Altogether, these results suggest that an increase in methionine and BCAA levels in the serum in response to dietary arginine deficiency is a key causative factor for hepatic TAG accumulation, and dietary adenine supplementation could disrupt this phenomenon by altering serum amino acid profiles.
Similar content being viewed by others
Introduction
Nutritional status of macronutrients significantly affects systemic metabolism of animals, and their imbalanced intake leads to a series of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD). NAFLD is defined as a series of hepatic diseases resulting from hepatic steatosis that develops without apparent excessive alcohol consumption. Among individuals with NAFLD, many remain under benign conditions (non-alcoholic fatty liver [NAFL]), whereas others exhibit non-alcoholic steatohepatitis (NASH) which can progress to liver inflammation, cirrhosis, and ultimately hepatocellular carcinoma1,2. Thus, an epidemic of NAFLD and NASH has increasingly given rise to clinical concerns worldwide.
For decades, the dietary imbalance of not only lipids or sugars but also other nutrients, including proteins/amino acids and nucleobases, has been reported to have significant impacts on neutral lipid accumulation in the liver, both in rodent models and in humans2,3,4,5. Because the detailed molecular mechanisms of NAFL progression have not yet been elucidated, there is no established definitive treatment for NAFLD; but dietary supplementation with some nutrients or small compounds is currently recommended3. For example, the purine nitrogenous base adenine can completely inhibit hepatic triacylglycerol (TAG) accumulation induced by a low-arginine diet, and the pyrimidine derivative orotic acid promotes fatty liver in rats6,7. Since it is known that dietary arginine deficiency alters nucleotide metabolism in the liver, thereby increasing orotic acid biosynthesis8,9, some researchers have raised the possibility that fatty liver induced by a low-arginine diet may be caused by increased orotic acid10. However, in this case too, the detailed molecular mechanisms still remain unclear as to how modified nucleotide metabolism or the related metabolites alter the hepatic lipid metabolism.
Many factors such as obesity, genetic background, viral infections, and dietary habits have been associated with NAFLD progression, but most of its underlying mechanisms and biomarkers for diagnosis have not been defined due to its high complexity2,3,11,12. A previous study demonstrated that a low-protein/amino acid diet and a low-arginine diet resulted in significant fatty liver development4,5, which led to the assumption that dietary arginine intake could have an important role in NAFLD progression. However, dietary arginine intake did not correlate with hepatic TAG levels, and a low-amino acid diet and a low-arginine diet induced fatty liver through a different mechanism, although both diets contained the same amounts of arginine13. This suggests that dietary amino acid concentrations are not primarily important; instead, serum amino acids are associated with hepatic lipid metabolism. In a previous study, a mathematical non-linear analysis based on a machine learning method revealed that a comprehensive serum amino acid profile, but not individual amino acid concentrations, correlated well with hepatic TAG levels in a rat model5.
Currently, many reports have suggested that serum amino acid profiles can be used as clinical diagnostic markers, since there is evidence for serum concentrations of some amino acids becoming up- or down-regulated in particular physiological disorders such as obesity, diabetes mellitus, some cancer types, and NAFLD14,15,16,17. We also demonstrated the correlation between serum amino acid profiles and hepatic TAG levels5. These results indicate that there is a strong link between serum amino acid profiles and hepatic lipid metabolism. However, since the available reports have used correlation analyses, we cannot determine whether the change in the serum amino acid profile is the cause or consequence of the disorder in question. Therefore, in the present study, we aimed to evaluate the possible role of serum amino acids in hepatic lipid accumulation by using our original methods: a cell-culture model and a non-linear machine leaning analysis. Furthermore, we illustrated how nucleobases are associated with serum amino acid profiles and affect lipid accumulation in the liver.
Results
A specific serum amino acid profile causes TAG accumulation in hepatocytes in a cell-autonomous manner
As previously reported5, a low-arginine (ΔArg) diet significantly induced TAG accumulation in the livers of rats in seven days, and serum amino acid profiles correlated well with liver TAG levels. Therefore, to evaluate the roles of serum amino acids in liver TAG accumulation, we compared the serum amino acid concentrations between ΔArg diet-fed rats and those fed a control diet. According to our results, the ΔArg diet increased or tended to increase the concentrations of four amino acids (methionine, histidine, glutamine, and glutamic acid), and reduced the concentrations of seven amino acids (cysteine/cystine, tryptophan, phenylalanine, tyrosine, arginine, threonine, and glycine), when compared to a control diet (Fig. 1a).
Next, we examined whether this specific serum amino acid profile in response to a ΔArg diet triggered TAG accumulation in the liver. For this, a culture medium that mimicked the serum composition of ΔArg diet-fed rats was prepared (see Supplementary Table S1). To this ΔArg-mimic medium, twice as much of the four up-regulated amino acids mentioned above as the control medium was added, and the seven down-regulated amino acids were not added. H4IIE rat hepatoma cells were cultured in control or ΔArg-mimic medium for 24 h, and the total TAG content was measured. The results demonstrated that the ΔArg-mimic medium significantly enhanced TAG accumulation in the cells when compared to the control medium (Fig. 1b), indicating that the specific amino acid profile of the hepatocytes’ surrounding environment could directly cause TAG accumulation. This also indicated that TAG accumulated in a cell-autonomous manner and under serum-free conditions.
Adenine supplementation restores TAG secretion in the liver of ΔArg diet-fed rats
It has been reported that adenine supplementation in a ΔArg diet completely abolishes TAG accumulation in the liver (Fig. 1c, Supplementary Table S2)6. Therefore, we tested the effects of adenine and purine metabolites on hepatic TAG accumulation in a rat model. Interestingly, among purine nitrogenous bases (adenine, guanine) and adenine-related metabolites (adenosine, adenosine monophosphate [AMP], and inosine monophosphate [IMP]), only adenine supplementation inhibited hepatic TAG accumulation (Fig. 1c,d, Supplementary Table S3). While a ΔArg diet inhibited hepatic TAG secretion, resulting in fatty liver13, our results indicated that dietary adenine, but not guanine, fully rescued TAG secretion in the liver (Fig. 1e, f).
Hepatic purine metabolism cannot explain the mechanism of fatty liver prevention by dietary adenine supplementation
To evaluate the effects of dietary arginine deficiency and the supplementation of adenine and related molecules on hepatic purine metabolism, liver samples from rats in Fig. 1d were used in the analysis of related metabolites (Fig. 2a). Interestingly, supplementation with a certain compound did not necessarily increase the concentration of its corresponding metabolite in the liver, and hepatic adenine levels did not correlate with hepatic TAG levels, suggesting that hepatic adenine per se was not very significant for fatty liver progression. In contrast, dietary adenine supplementation increased hepatic IMP levels, which negatively correlated with liver TAG levels, while no other tested metabolite displayed any correlation (Fig. 2a).
In light of these results, we evaluated rats fed a diet containing three times as much IMP or those received IMP injection directly into the tail vein. The strong dietary IMP supplementation only slightly decreased ΔArg diet-induced hepatic TAG accumulation, while the direct intravenous injection did not show any significant effects on hepatic TAG levels (Fig. 2b,c). Collectively, these results indicate that the inhibition of ΔArg diet-induced fatty liver caused by dietary adenine occurs through a mechanism that cannot be explained by changes in purine metabolite levels in the liver.
Multi-layer perceptron (MLP) analysis can predict the suppression of TAG accumulation only using serum amino acid profiles
In an earlier study from our group, we evaluated 135 data sets with serum amino acid concentrations and hepatic TAG levels in rats fed 27 different diets with varying amino acid compositions. A machine learning program based on MLP was established to predict individual hepatic TAG levels using the data on serum amino acid concentrations5. Based on this method, serum amino acid profiles and hepatic TAG levels were shown to exhibit a good correlation. Therefore, we analyzed the serum amino acid profiles of rats fed the purine-supplemented diets in order to predict their hepatic TAG accumulation levels by using this method.
Figure 3a illustrates the program output of TAG values (“Predicted”) based only on the serum amino acid data and comparison with the measured hepatic TAG levels (“True”). Remarkably, the inhibitory effect of adenine supplementation on TAG accumulation was estimated with high accuracy, suggesting that adenine supplementation to the ΔArg diet would probably change the serum amino acid profile. Thus, we compared the serum amino acid profiles of each rat (ΔArg, ΔArg + adenine, ΔArg + adenosine, ΔArg + AMP, and ΔArg + IMP), and found that the serum amino acid profiles of the “fatty liver group” (ΔArg, ΔArg + adenosine, ΔArg + AMP, ΔArg + IMP) were quite similar to each other, but that of the ΔArg + adenine group greatly differed (Fig. 3b, Supplementary Table S4). These data suggested that adenine supplementation to a ΔArg diet, but not that of the other metabolites, changed the serum amino acid profile towards a “non-inducible pattern” for hepatic lipid accumulation.
Alterations in the serum amino acid profile prevent hepatic TAG accumulation caused by a ΔArg diet
Finally, to confirm the causative effect of serum amino acid profiles on hepatic TAG accumulation in vivo, we conducted different dietary interventions with the aim of perturbating serum amino acid compositions. Comparing the serum amino acid concentrations of rats fed a ΔArg diet and a ΔArg + adenine diet, the levels of methionine, histidine, and branched-chain amino acids ([BCAAs]; valine, leucine, isoleucine) were found to be much lower in ΔArg + adenine-fed rats (Fig. 3b,c). Subsequently, the concentration of each of these amino acids was reduced by two thirds in the ΔArg diet and rats were fed with this new diet composition for seven days. As expected, the deficiency of methionine or BCAAs in the ΔArg diet dramatically changed serum amino acid profiles and significantly abolished hepatic TAG accumulation, whereas histidine deficiency had little impact (Fig. 4, Supplementary Table S3, 4). Taken together, our results suggested that the specific serum amino acid profile formed in response to a ΔArg diet was able to regulate the lipid metabolism in hepatocytes, where attenuated TAG secretion caused TAG accumulation, leading to the development of fatty liver.
Discussion
Dietary imbalance of some nutrients, including proteins/amino acids and nitrogenous bases, has been reported to have a significant impact on neutral lipid accumulation in the liver3,6. The amino acids, namely arginine, methionine, threonine, tryptophan, and glutamine has been suggested in NAFL3,5,18, but the underlying molecular mechanisms for this phenomenon have been described in a highly controversial manner with contradictory results. For example, while a methionine/choline-deficient diet is well known to induce NAFLD, a methionine-deficient diet prevents fatty liver progression in ob/ob mice19,20. Furthermore, a low-arginine or low-threonine diet induced fatty liver development in rats, whereas arginine or threonine supplementation to an amino acid-deficient diet failed to reverse fatty liver development5. These results strongly suggest that monitoring the intake of a single amino acid is not sufficient to understand the whole scenario of NAFL progression associated with amino acid nutrition. In this study, we provide another perspective for this relationship: the serum amino acid profile.
Adenine reportedly has an inhibitory effect on NAFL progression induced by a low-arginine diet, although the underlying mechanism is still unknown6. Some metabolites in purine metabolism, such as uric acid, are known as antioxidants; thus, it is possible that antioxidative properties of these molecules may have hepatoprotective effects21. If adenine itself is a bioactive molecule for controlling hepatic lipid metabolism, the ingested adenine should reach the liver through blood circulation. In addition, other purine metabolites should also change hepatic TAG levels because they could affect the adenine concentration through nucleotide metabolism. However, in the present study, even when adenine was supplemented in the diet, serum adenine concentrations were very low, often below the detectable level. Moreover, the hepatic adenine content did not correlate with hepatic TAG levels, although IMP actually increased adenine concentration in the liver (Fig. 2a). Since we previously discovered that dietary amino acid composition can dramatically affect serum amino acid profiles, changing it into an unexpected pattern5, we hypothesized that dietary adenine intake would also modify the serum amino acid profiles, which in turn would lead to a down-regulation of hepatic TAG accumulation. Indeed, oral adenine administration, but not other metabolites, modified serum amino acid profiles, and a medium amino acid composition that was similar to the serum of ΔArg diet-fed rats enhanced TAG accumulation in a cultured hepatocyte model (Fig. 1a,b). The media used in this study were serum-free, indicating that the amino acid profile was a sufficient signal for cellular metabolic regulation, regardless of any hormonal stimulation or neuronal input. These results illustrate a novel type of “metabolic regulatory amino acid signal” driven by comprehensive serum amino acid profiles.
In the current study, we used data of 20 protein-composing amino acids plus cystine for machine learning analyses, but it was not clear whether all these amino acids were indeed necessary for signal transduction. Although the ΔArg diet increased both methionine and histidine levels in the serum, a ΔArg/ΔHis diet did not exhibit an apparent effect on hepatic TAG levels, whereas a ΔArg/ΔMet diet significantly lowered these levels (Figs. 3b,c, 4). These results suggest that not all amino acids are essential to determine hepatic TAG levels. In addition, serum BCAA levels were not increased by a ΔArg diet, but were decreased by adenine supplementation, and hepatic TAG accumulation was inhibited by a ΔArg/ΔBCAA diet (Fig. 2b, 3b), implying that not only the absolute amino acid concentrations but also their relative concentrations are important. Furthermore, it was shown that the activities of peroxisome proliferator-activated receptor α (PPARα) and sterol regulatory element-binding protein-1c (SREBP1c), which are generally considered to be important transcription factors for the regulation of hepatic lipid metabolism, were not affected by amino acid deficiency5, suggesting that another mechanism is likely to be involved. Further research is necessary to understand which specific combinations of amino acids are actually functional and how these signals are recognized by the hepatocytes, leading to modifications in the activities of lipid metabolic machinery.
Altogether, we conclude that changes in comprehensive serum amino acid profiles in response to dietary amino acid compositions play a causative role in the regulation of lipid metabolism in the liver, and dietary adenine interferes with this signal transmission by perturbating serum amino acid profiles. This discovery should provide a novel insight into NAFLD pathophysiology. Although there are several exceptions , such as hepatitis C virus-induced NAFLD, which is unlikely to have a direct link with serum amino acids22, a certain part of the mechanism of pathogenesis should be explained by the amino acid signals that we discovered. This will lead to the design of useful diagnostic methods and establishment of effective prevention or treatment for NAFLD.
Materials and methods
Materials
For animal experimental diets, the vitamin mixture, mineral mixture, cellulose powder, and corn starch were purchased from Oriental Yeast Co. (Tokyo, Japan), while soybean oil was acquired from Nacalai Tesque (Tokyo, Japan). Solutions such as 10 × Earle’s buffered salt solution (EBSS) and 100 × MEM vitamin solution were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Fetal bovine serum (FBS) was obtained from Sigma-Aldrich. Penicillin and streptomycin were obtained from Banyu Pharmaceutical Co., (Ibaraki, Japan). Other chemicals were of commercially available reagent grade.
Animal experiments
Five-week-old male Wistar rats were purchased from Charles River Japan (Kanagawa, Japan). The rats were caged individually and maintained at 24 ± 1 °C with 50–60% humidity and a 12 h light/dark cycle (8:00–20:00/ 20:00–8:00). They were allowed free access to food and water during the experiment.
Prior to the experiments, all rats were fed normal chow for three days and a control (CN) diet containing 15% (w/w) amino acids (Supplementary Table S1) for the next four days as a prefeeding period. The animals were then divided into experimental groups. Thereafter, each group was given either the CN diet or each experimental diet for seven days. In a specific amino acid-deficient diet, the indicated amino acid concentration was 1/3 of that of the CN diet, and the concentration of the nucleotide supplement was 3 g/kg unless otherwise stated. For IMP injections, an inosine-5′-monophosphate disodium salt solution (100 mM, Sigma-Aldrich) was injected in the tail vein at days 1, 3, and 5 after beginning the experimental diets. In the control group, the same volume of saline solution was injected in the tail vein. All the diets were self-made. Throughout the experimental period, the body weight and food intake of all rats were measured at 10:00 AM every day. For tissue collection, rats were anesthetized with isoflurane (DS Pharma Animal Health, Tokyo, Japan) and then samples were obtained from the rats’ carotid arteries and livers. The serum was prepared soon after blood collection and liver samples were immediately frozen in liquid nitrogen. All samples were stored at -80 °C for future use.
All animal care and experiments conformed to the Guidelines for Animal Experiments of The University of Tokyo and were approved by the Animal Research Committee of The University of Tokyo.
Cell culture and experiments
H4IIE-C3 cells (a rat hepatoma cell line, ATCC CRL-1600) were grown in DMEM supplemented with 10% FBS and antibiotics under 5% CO2 at 37 °C. Upon reaching sub-confluency, the medium was changed to an experimental serum-free medium (Supplementary Table S2), and the cells were further cultured for 24 h.
Liver/cellular TAG measurement
Total lipids in the liver were extracted according to Folch’s method23 with small modifications. The frozen liver was homogenized in methanol:chloroform solution (1:2, v/v), followed by the addition of 20% volume of 0.8% KCl solution and centrifugation at 13,000 × g, at 4 °C for 10 min. Then, the organic (chloroform) layer was collected, the solvent was evaporated, and the remaining lipids were reconstituted in isopropanol. Similarly, lipids in cultured cells were extracted with a methanol:chloroform solution (1:1, v/v) and a saturated NaCl solution. The TAG content in the lipid extract was measured using Triglyceride E-test Wako (Wako, Osaka, Japan).
MLP analysis
We built an MLP program using the libraries Keras, version 2.3.1, and TensorFlow, version 2.1.0, previously5, and we used the program in the present study with no modifications. The training data set was composed of serum amino acid profiles and liver TAG levels of each rat that were obtained in the same previous study. The MLP network configuration was as follows: a 21-dimensional input (20 amino acids + cystine), 4 hidden layers with 300, 300, 300, and 100 neurons from the input direction, and a 1-dimensional output of liver TAG levels. Dropouts were provided in each layer and set to 0.5, 0.4, 0.4, 0.4, and 0.3 from the input direction. The maximum learning epoch was set to 10,000. If the loss values did not update after more than 1,000 training epochs, “early stopping” was used to stop the training. Mean square error was used for the Loss function, and RMSprop for the optimization function. The activation function used ReLU in each layer. The trained model was used to predict liver TAG levels from untrained data sets of serum amino acid concentrations.
Serum and liver metabolite analysis
For serum metabolite extraction, 50 µL of serum samples were mixed on ice with 120 μL methanol containing internal control substances: 25 μM 2-morpholinoethanesulfonic acid and 100 μM methionine sulfone. After centrifugation (16,000 × g for 10 min at 4 °C), 130 μL of supernatant was mixed with 250 μL ultrapure water and subjected to ultrafiltration using 3 kDa cutoff filters (Amicon Ultra 3 K device, Merck, Darmstadt, Germany), followed by 30 min of evaporation and 6 h of lyophilization.
For liver metabolite extraction, approximately 100 mg of liver pieces were homogenized in 500 μL of methanol containing internal controls. The homogenates were diluted with 250 μL of ultrapure water, and 600 μL of each homogenate was mixed with 400 μL chloroform. Following centrifugation (16,000 × g for 5 min at 4 °C), 800 μL of the upper phase was collected and subjected to 30 min of evaporation. Then, 300 μL of ultrapure water was added, followed by ultrafiltration and lyophilization.
The lyophilized metabolite samples were reconstituted in 200 μL ultrapure water, further diluted if necessary, and then subjected to LC–MS/MS (LCMS-8030, Shimadzu, Kyoto, Japan) analysis, using Method Package for Primary Metabolites ver. 2 (Shimadzu) according to the manufacturer’s protocol.
TAG secretion assay
Six-week-old male Wistar rats were fed CN or ΔArg diets with or without nitrogenous base supplementation for seven days. Then, 200 mg/kg body weight of tyloxapol dissolved in 0.9% NaCl (Sigma-Aldrich) was administered into the tail vein (200 mg/kg body weight) under isoflurane anesthesia (DS Pharma Animal Health) and blood was collected 0, 1, 2, and 4 h after injection. TAG concentrations in the sera were measured using Triglyceride E-test Wako (Wako). Because tyloxapol is an inhibitor of endogenous lipoprotein lipase, TAG accumulation in the blood after its injection under fasting conditions reflects TAG secretion from the liver. Thus, the TAG increasing rate in the serum after tyloxapol injection was interpreted as the TAG secretion activity in the liver.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM), unless otherwise stated. Comparisons between two groups were performed using Student’s t-test. Comparisons among more than two groups were performed using one-way analysis of variance (ANOVA). If the p value obtained from the ANOVA test was < 0.05, the Tukey–Kramer post-hoc test was performed. Values of p < 0.05 were considered statistically significant. All statistical calculations were performed using JMP Pro (SAS Institute Inc., Cary, NC, USA).
Data availability
All data shown in this manuscript are available from the corresponding author on reasonable request.
References
Spengler, E. K. & Loomba, R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin. Proc. 90, 1233–1246 (2015).
Zivkovic, A. M., German, J. B. & Sanyal, A. J. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 86, 285–300 (2007).
Hernandez-Rodas, M., Valenzuela, R. & Videla, L. Relevant aspects of nutritional and dietary interventions in non-alcoholic fatty liver disease. Int. J. Mol. Sci. 16, 25168–25198 (2015).
Toyoshima, Y., Tokita, R., Taguchi, Y., Akiyama-akanishi, N. & Takenaka, A. Tissue-specific effects of protein malnutrition on insulin signaling pathway and lipid accumulation in growing rats. Endocr. J. 61, 499–512 (2014).
Nishi, H. et al. Importance of serum amino acid profile for induction of hepatic steatosis under protein malnutrition. Sci. Rep. 8, 1–11 (2018).
Aoyama, Y., Yoshida, A. & Ashida, K. Effect of some dietary additions to either an arginine- devoid diet or a diet supplemented with orotic acid refed after starvation on liver lipid content during essential fatty acid deficiency in rats. J. Nutr. 111, 895–906 (1981).
Marchetti, M., Puddu, P. & Caldarera, C. Metabolic aspects of ‘orotic acid fatty liver’. Nuleotide control mechanisms of lipid metabolism. Biochem. J. 92, 46–51 (1964).
Hassan, A. S. & Milner, J. A. Alterations in liver nucleic acids and nucleotides in arginine deficient rats. Metabolism 30, 739–744 (1981).
Milner, J. A. Metabolic aberrations associated with arginine deficiency. J. Nutr. 115, 516–523 (1985).
Milner, J. A. Mechanism for fatty liver induction in rats fed arginine deficient diets. J. Nutr. 109, 24–31 (1979).
Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).
Wong, V.W.-S., Adams, L. A., de Lédinghen, V., Wong, G.L.-H. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 15, 461–478 (2018).
Otani, L. et al. Low-arginine and low-protein diets induce hepatic lipid accumulation through different mechanisms in growing rats. Nutr. Metab. (Lond) 17, 1–13 (2020).
Noguchi, Y. et al. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am. J. Clin. Nutr. 83, 513–519 (2006).
Gaggini, M. et al. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology 67, 145–158 (2018).
Lynch, C. J. & Adams, S. H. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat. Rev. Endocrinol. 10, 723–736 (2014).
Miyagi, Y. et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 6, e24143 (2011).
Aoyama, Y., Yasui, H. & Ashida, K. Effect of dietary protein and amino acids in a choline-deficient diet on lipid accumulation in rat liver. J. Nutr. 101, 739–745 (1971).
Itagaki, H., Shimizu, K., Morikawa, S., Ogawa, K. & Ezaki, T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int. J. Clin. Exp. Pathol. 6, 2683–2696 (2013).
Malloy, V. L. et al. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice. Metabolism 62, 1651–1661 (2013).
Ames, B. N., Cathcart, R., Schwiers, E. & Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U. S. A. 78, 6858–6862 (1981).
Patel, A. & Harrison, S. A. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol. Hepatol. 8, 305–312 (2012).
Folch, J. & Lees, M. S. G. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 55, 999–1033 (1957).
Acknowledgments
We thank the members of Professor Takahashi’s laboratory for their valuable support and discussion and Ms. Tomomi Ueda and Ms. Noyumi Nakamura of Dr. Ito’s laboratory for their technical support. We also appreciate Drs. Susan Hall and Narula Acharan Singh (University of North Carolina at Chapel Hill) for imparting scientific suggestions to improve the manuscript. Finally, we would like to thank Editage (www.editage.com) for their English language editing services.
Funding
This work was supported in part by Grants-in-Aid for Scientific Research (B) #15H04583 and Scientific Research (B) #24380152 from the Japan Society for the Promotion of Science (JSPS) to F.H.; Grant-in-Aid for the Scientific Research (S) #25221204 and Scientific Research (A) #18H03972, as well as Core-to-core program A. A. Advanced Research Networks from JSPS and R&D matching funds on the Field for Knowledge Integration and Innovation from the Bio-oriented Technology Research Advancement Institution (NARO), to S-I.T. Grant-in-Aid for the Scientific Research (C) #19K06436 from JSPS to D.Y.; Collaborative research with For Days Co., Ltd. to K.I.
Author information
Authors and Affiliations
Contributions
H.N, D.Y., M.M., Y.G., F.H., and S-I. T. designed the experiments. H.N. and D.Y. conducted the wet lab experiments and M.M. performed machine learning analysis. K.I., F.H., and S-I. T critically supervised the study. H.N, D.Y., M.M., F.H., and S-I. T. wrote this manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Nishi, H., Yamanaka, D., Masuda, M. et al. Alteration of serum amino acid profiles by dietary adenine supplementation inhibits fatty liver development in rats. Sci Rep 10, 22110 (2020). https://doi.org/10.1038/s41598-020-79234-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-020-79234-w
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.